The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV-1, Drug Therapy, Combination, Reverse Transcriptase Inhibitors, Anti-HIV Agents, 9-(2-phosphonylmethoxypropyl)adenine
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Have completed another study on tenofovir DF without toxicity. Are willing to use intrauterine or effective barrier methods of birth control, both men and women, during the study and for 30 days following tenofovir DF treatment. Exclusion Criteria Patients will not be eligible for this study if they: Are taking drugs that may damage the kidney (nephrotoxic) including aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, vancomycin, and oral or IV ganciclovir. Are taking agents that affect kidney function, such as probenecid. Are receiving systemic chemotherapy. Are taking systemic corticosteroids. Are taking experimental drugs except those that are approved by Gilead. Are currently participating in the GS-99-908 or GS-00-912 (expanded access) studies. Are pregnant or breast-feeding.
Sites / Locations
- East Bay AIDS Ctr
- Tower ID Med Associates
- Pacific Horizons Med Group
- Harbor - UCLA Med Ctr
- Univ of Colorado / Health Science Ctr
- Physicans Home Service
- Steinhart Medical Associates
- Dr Gerald Pierone Jr
- Northstar Med Clinic
- CRI New England
- Univ of Minnesota
- Univ of Rochester Med Ctr
- Research & Education Group
- Hershey Med Ctr
- Anderson Clinical Research
- Roger Williams Med Ctr
- Southwest Infectious Diseases Associates
- Thomas Street Clinic
- Dr Philip C Craven